All News

Rheumatology,Roundup,2023

Rheumatology Roundup - ACR 2023

Jack Cush, MD

Drs. Jack Cush and Arthur Kavanaugh discuss highlights and key takeaways from ACR 23.

Read Article
RheumNow Podcast square

ACR Convergence Preview (11.10.2023)

Jack Cush, MD

Dr. Jack Cush reviews this past week's news on RheumNow.com and suggests a learning plan for those wanting to consume the upcoming ACR Convergence 2023 meeting. 

Read Article
RheumNow Podcast square

Sleep Apnea Smart Watches (10.13.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal reports and regulatory approvals from this past week on RheumNow.com.

Read Article
RheumNow Podcast square

PMR & Popeye's Spinach (10.6.2023)

Jack Cush, MD

Dr. Jack Cush reviews the big PMR reports from this week along with other journal reports from RheumNow.com.

Read Article
PMR,flag

SAPHYR Trial: Sarilumab Wins in Relapsing Polymyalgia Rheumatica

Jack Cush, MD

NEJM reported today that polymyalgia rheumatica (PMR) patients who fail to respond to standard doses of prednisone therapy, were significantly better when given the IL-6 inhibitor sarilumab (than placebo).

Read Article
think,know,guess,idea

Advice on Multi-Drug Failures in RA

Jack Cush, MD

What’s your next best approach to the rheumatoid arthritis (RA) patient who has failed several DMARDs and biologics?  In such cases you have to either reconsider the diagnosis (especially if seronegative) or reach into your bag of tricks.  

Read Article
RheumNow Podcast square

RheumNow Podcast with Special Guest Dr. Michael Weinblatt (9.22.2023)

Jack Cush, MD

Dr. Jack Cush is joined by Dr. Michael Weinblatt as they discuss this weeks news and journal reports, including difficult RA, HLA typing and abatacept responses and new regulatory decisions. 

Read Article
RA,Rx,puzzle

Biologic Adherence and Drug Survival in RA Patients

Jack Cush, MD

A real-world rheumatoid arthritis (RA) cohort study from Israel shows significant variability of drug survival using biologic disease-modifying anti-rheumatics drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs).

Read Article
APTURA 1 study of tocilizumab biosimilar. Not surprisingly no difference. I'm excited about this product. Hopefully be the end to our tocilizumab supply issues and significant societal savings Abstr#0445 #ACR23 @RheumNow https://t.co/qvP7LCeAkm https://t.co/Zb1FUAlXlz
Richard Conway  ( View Tweet)
Debaters and moderators acknowledge IL6i may not be the only steroid sparing agents that would work for #GCA. Abatacept, secukinumab, JAKi are being evaluated #greatdebate @rheumnow #ACR23

TheDaoIndex KDAO2011 ( View Tweet)

@philseo on why we SHOULD use IL-6i in GCA and PMR 1) Infection risk similar to TNFi 2) Too many (63%) pts remain on steroids at 1-2 yrs 3) May accelerate remission 4) Steroids are Bad, even at low doses @RheumNow #ACR23 https://t.co/muPPcAc6LC
Robert B Chao, MD  ( View Tweet)
#GreatDebate #ACR23 @RheumNow Advanced Rx 1st line in PMR/GCA @philseo IL-6 research in RA (STREAM, MOBILITY): safety of toci, sarilumab - compares to ADA Ifn risk driven by GCs GUSTO: TCZ w/ only 3d GC pulse - 13/18 in remission 24, 52w PMR: "its not just a little bit of pred" https://t.co/sAlQ0pttcq
Eric Dein  ( View Tweet)
Should IL-6i be first line in GCA/PMR? Dr. Spiera says steroids work, are cheap; no evidence of using IL6i early in disease. there had been cases where pts still had active vasculitis while on IL-6i. He starts with steroids first then add IL6i #GreatDebate #ACR23 @rheumnow https://t.co/Oq5Q9HFtW3
TheDaoIndex KDAO2011 ( View Tweet)
Good Treatment review of biologics (IL-1, IL-6) in systemic JIA (Stills) including complications of #MAS and lung disease; also info on horizon therapies like JAK inhibitors and IL-18 targeting and novel biomarkers (calgranulins, IL-18 and CXCL9) https://t.co/Cbd7bKdIbb https://t.co/d9tn9fmSAy

Links:

Dr. John Cush RheumNow ( View Tweet)
I underestimated how much joy not-bankrupting our healthcare system would bring me ADA & RTX biosimilars have been wonderful; excited for IL6's to join the party @RheumNow #ACR23 Abstr0445 https://t.co/HGwi37rZpd
Mike Putman EBRheum ( View Tweet)
Good Treatment review of biologics (IL-1, IL-6) in systemic JIA (Stills) including complications of #MAS and lung disease; also info on horizon therapies like JAK inhibitors and IL-18 targeting and novel biomarkers (calgranulins, IL-18 and CXCL9) https://t.co/ACe7nDDwop https://t.co/lV66WerkAp

Links:

Dr. John Cush RheumNow ( View Tweet)
Metanalysis of 26 studies (2252) pts w/ HBsAg-/HBcAb+ RA treated with b/tsDMARDs, shows the pooled HBV reactivation rate was 2.0% HBV reactivation higher w/ RTX (9%), ABA (6%), JAKi (1%); none w/ IL-6i or TNF-i More reactivation if pt is HBsAb- (OR=4.56) https://t.co/V60nkUSpjj https://t.co/jnZKnY0Zuk

Links:

Dr. John Cush RheumNow ( View Tweet)
Tocilizumab Use in #GCA. In 10 yrs, 114 GCA pts started on TCZ after mean 4.5 mos & Rx for 2.3 yrs. GCA Relapse rates: - before TCZ 0.84/PY - on TCZ 0.28/PY (P<0.001) - post TCZ D/C 0.64/PY 52 pts D/C TCZ after 16.8 mos & 27 (52%) relapsed after 8.4 mo https://t.co/D3INiMdC4U https://t.co/aD2rijR6xd

Links:

Dr. John Cush RheumNow ( View Tweet)
IL-6 Inhibitors in #PMR: Give early or late? https://t.co/Hg7ZJJxaGD https://t.co/cJdnTPI3YD

Links:

Dr. John Cush RheumNow ( View Tweet)
SAPHYR Trial: Sarilumab Wins in Relapsing Polymyalgia Rheumatica NEJM reported today that #PMR patients who fail to respond to standard doses of prednisone therapy, were significantly better when given the IL-6 inhibitor sarilumab (than placebo). https://t.co/k5SAshxdsg https://t.co/tMtRHn2C6j

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×